PharmaCyte Biotech Appoints American Stock Transfer as New Stock Transfer Agent
July 09 2015 - 9:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that, effective July
10, 2015, American Stock Transfer & Trust Company (“AST”) will
replace Signature Stock Transfer as its stock transfer and dividend
disbursing agent.
The Chief Executive Officer of PharmaCyte
Biotech, Kenneth L. Waggoner, commented on PharmaCyte Biotech’s new
stock transfer agent, “We are extremely pleased to announce that we
have appointed AST to be our new stock transfer agent. We are
confident that our partnership with this fine organization will
provide our shareholders with superior customer service and
support. In addition, it will enable us to have access to the
industry’s leading management resources and will ensure us the
highest quality of operational process that we believe will yield
tangible financial benefits to PharmaCyte Biotech and its
shareholders.”
AST and its affiliates are leading providers of
registry services and technology to financial market participants
around the globe. With over 40 years of experience, AST is known
for providing a superior customer service experience, which is
supported by ongoing investments to technology, people and service
offerings. AST has premier in-house call centers, innovative
software and processing systems that set the industry standard.
AST provides comprehensive stock transfer and
employee plan services to over 2,800 public companies and maintains
approximately 6,000 issues. AST’s clients are located throughout
the United States and in over 22 foreign countries, ranging in size
from initial public offerings to Fortune 100 companies. Founded in
1971 and headquartered in New York, AST provides clients around the
globe with customized solutions to fit their specific needs along
with access to the best systems, services, processes and products
available today.
On and after July 10, 2015, all inquiries and
correspondence related to stockholder records, transfer of shares,
lost certificates, dividend checks or change of address requests
should be directed to AST. If you have questions, please call AST
at (800) 937-5449 or email AST at info@amstock.com. AST can also be
contacted via mail at:
PharmaCyte Biotech
Inc.
c/o American Stock Transfer & Trust Company,
LLC
6201 15th
Avenue
Brooklyn, NY 11219
On July 10, 2015, welcome letters with detailed
information about AST will be mailed directly to all PharmaCyte
Biotech registered shareholders with instructions on how to access
their account through AST.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company focused on developing and
preparing to commercialize treatments for cancer and diabetes based
upon a proprietary cellulose-based live cell encapsulation
technology known as Cell-in-a-Box®. This unique and patented
technology will be used as a platform upon which treatments for
several types of cancer, including advanced, inoperable pancreatic
cancer, and diabetes are being built. PharmaCyte Biotech's
treatment for pancreatic cancer involves low doses of the
well-known chemotherapy prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. These capsules are placed as close to the
tumor as possible to enable the delivery of the highest levels of
the cancer-killing drug at the source of the cancer. This "targeted
chemotherapy" has proven remarkably effective in past clinical
trials. PharmaCyte Biotech is also working towards improving the
quality of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing
treatments for cancer based upon chemical constituents of the
Cannabis plant, known as cannabinoids. In doing so, PharmaCyte
Biotech is examining ways to exploit the benefits of Cell-in-a-Box®
technology in optimizing the anticancer effectiveness of
cannabinoids, while minimizing or outright eliminating the
debilitating side effects usually associated with cancer
treatments. This provides PharmaCyte Biotech the rare opportunity
to develop “green” approaches to fighting deadly diseases, such as
cancer of the pancreas, brain and breast, which affect hundreds of
thousands of individuals worldwide every year.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com